Regan, Meredith M.
,
Pagani, Olivia
Francis, Prudence A.
Fleming, Gini F.
Walley, Barbara A.
Kammler, Roswitha
Dell’Orto, Patrizia
Russo, Leila
Szőke, János
Doimi, Franco
Villani, Laura
Pizzolitto, Stefano
Öhlschlegel, Christian
Sessa, Fausto
Peg Cámara, Vicente
Rodríguez Peralto, José Luis
MacGrogan, Gaëtan
Colleoni, Marco
Goldhirsch, Aron
Price, Karen N.
Coates, Alan S.
Gelber, Richard D.
Viale, Giuseppe
Funding for this research was provided by:
National Cancer Institute (CA75362, SWOG (US NIH CA32102); Alliance/CALGB (US NIH U10-CA180821); ECOG-ACRIN (US NIH CA21115 and CA16116); NSABP/NRG (US NIH U10-CA-12027, U10-CA-69651, U10-CA-37377, U10-CA-69974); NCIC-CTG (US NIH CA077202)
Susan G. Komen for the Cure (KG080081)
National Health and Medical Research Council (351161 and 510788)
Canadian Cancer Society Research Institute (015469 and 021039)
Breast Cancer Research Foundation
Cancer Research UK (A15955)
National Institute for Health Research
Pfizer
Ipsen Fund
Swiss Group for Clinical Cancer Research
Oncosuisse
Fontier Science and Technology Research Foundation
Article History
Received: 24 September 2015
Accepted: 14 October 2015
First Online: 22 October 2015
Compliance with ethical standards
:
: Dr. Francis reports uncompensated presentation of results of SOFT and TEXT for Pfizer at an international meeting. The remaining authors declare that they have no conflict of interest.